Company
Headquarters: Berlin, Germany
Employees: 300
CEO: Mr. Matthias Gaertner
€370.9 Million
EUR as of Jan. 1, 2026
US$435.5 Million
| Company | Market Cap (USD) |
|---|---|
| McKesson Corporation | $102.42 B |
| Cencora, Inc. | $65.71 B |
| Cardinal Health, Inc. | $48.88 B |
| Shanghai Pharmaceuticals Holding Co. Ltd | $9.44 B |
| Henry Schein, Inc. | $9.32 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures drugs for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.
Medios AG has the following listings and related stock indices.
Stock: FSX: ILM1 wb_incandescent
Stock: XDUS: ILM1 wb_incandescent
Stock: XETR: ILM1 wb_incandescent